Loading...
Loading...
Size: 10mg
Cellular Peptide
In stock · Ships same day · Free shipping over $150
Technical specifications
Molecular Profile
Synthetic cyclic heptapeptide and active metabolite of melanotan II.
Storage Requirements
Lyophilized (powder)
-20°C · stable long-term
Reconstituted / in solution
2-8°C · use within 30 days
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from the alpha-MSH analog Melanotan II, with selective activity at MC3R and MC4R receptors in the hypothalamus and limbic system. Unlike vascular-acting compounds such as PDE5 inhibitors or alprostadil, PT-141 operates entirely through the central nervous system — activating MC4R on hypothalamic paraventricular nucleus neurons to initiate downstream signaling through oxytocin and dopamine pathways that modulate sexual desire and arousal at the neurological level. The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first centrally-acting agent approved for this indication. Clinical trials demonstrated that PT-141 significantly increased sexual desire, arousal, and satisfying sexual events compared to placebo in both female and male subjects across multiple Phase 2 and Phase 3 studies published in the Journal of Sexual Medicine. What distinguishes PT-141 from all other sexual health compounds is its mechanism — it enhances desire rather than simply enabling mechanical function, addressing the neurological component of sexual response that vascular agents cannot reach. This Pepcell product is a research-grade compound for laboratory investigation, not the FDA-approved Vyleesi pharmaceutical product.
Activates MC4R receptors on hypothalamic paraventricular nucleus neurons, triggering downstream oxytocin and dopamine signaling cascades that modulate sexual desire and arousal. This central nervous system mechanism is fundamentally distinct from PDE5 inhibitors (vascular cGMP) and alprostadil (vascular cAMP), which act on peripheral blood vessel smooth muscle without affecting desire.
Increases sexual desire, arousal, and satisfying sexual events through neurological activation rather than mechanical vascular effects. Phase 3 clinical trials (RECONNECT) demonstrated statistically significant increases in desire domain scores and reductions in distress associated with low sexual desire. PT-141 is the only compound class that directly addresses the desire component of sexual response.
Clinical research has demonstrated efficacy in both male and female subjects, as the melanocortin MC4R pathway governs sexual arousal and desire across sexes. The FDA approved bremelanotide (Vyleesi) for premenopausal women with HSDD in 2019, while earlier Phase 2 studies in men showed significant improvements in erectile function through this same central pathway.
Published research protocols reference subcutaneous administration. Store refrigerated at 2-8°C.
Every batch is independently analyzed by a third-party laboratory for purity and identity before release. A batch-specific Certificate of Analysis (COA) is available for each lot.
Purity
99.1%
Lab
Janoshik Analytical Laboratory
Batch
PT141-2025-001
Test Date
2025-01-31
Orders placed before our daily cutoff ship the same business day. Free shipping on orders over $150, with tracking emailed as soon as your order leaves our facility.
Shipment protection covers your order against loss or damage in transit — if a protected order is lost or arrives damaged, our support team will arrange a replacement or resolution.
For in-vitro research and laboratory use only. This product is not a drug, supplement, food, or cosmetic, and has not been evaluated by the FDA.
Use is restricted to qualified researchers and laboratories operating within all applicable institutional, legal, and ethical guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
PT-141 (bremelanotide) is the same active peptide in the FDA-approved product Vyleesi, which was approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. However, this Pepcell product is a research-grade compound manufactured for laboratory investigation and is not the Vyleesi pharmaceutical product. Individuals seeking bremelanotide for medical use should consult a physician.
PT-141 works through central nervous system MC4R melanocortin receptors to enhance sexual desire and arousal at the neurological level. Sildenafil (Viagra) inhibits PDE5 enzyme in penile blood vessels to maintain erections by preventing cGMP breakdown. These are completely different mechanisms — PT-141 affects desire (wanting), while PDE5 inhibitors affect mechanical vascular function (ability). They address different components of sexual response.
Reconstitute lyophilized PT-141 with bacteriostatic water by slowly injecting along the vial wall. The cyclic heptapeptide structure provides good stability in solution. Store unreconstituted peptide at -20°C. After reconstitution, refrigerate at 2-8°C and use within 30 days.
Each PT-141 batch undergoes independent HPLC purity analysis and mass spectrometry identity verification at Janoshik Analytical Laboratory, confirming both purity and correct cyclic peptide structure. Current batches test at 99.1% purity with batch-specific Certificates of Analysis provided.
This research-grade PT-141 (bremelanotide) is sold exclusively for in-vitro research, melanocortin receptor studies, and laboratory investigation. While bremelanotide is FDA-approved as Vyleesi for a specific clinical indication, this Pepcell product is not manufactured to pharmaceutical standards and is not intended for human consumption or self-administration.